Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
51
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
21/01/21
We include BASF’s preliminary figures 2020 to give some flavour of the profitability and the potential drivers in Q4 20. Our 2021 and 2022 remain ...
20/01/21
Santa Claus seems to be dressed in BASF’s colours and bringing strong end-of-year ‘presents’. The earlier steps of the chemicals’ value chain came in ...
18/01/21
Rephrasing our headline, it could have been ‘Buying into something tiny’. We are still struggling with the financial offer (€1,378m) and potential ...
18/01/21
Being top dog in an oligopoly industry (Flavours & Fragrances) growing at a steady 4-5% annual clip means that Givaudan (Reduce, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO